ADM’s Probiotic Shows Promise for Constipation: Study

Why It Matters

If confirmed in humans, BPL1 could become a natural, probiotic alternative to traditional laxatives, opening a new revenue stream for ADM and addressing a widespread gastrointestinal issue. The findings also add scientific weight to the growing market for microbiome‑based therapeutics.

Key Takeaways

• BPL1 increased stool number, weight, and moisture in constipated rats.
• High dose (3×10⁹ CFU) showed stronger effects than low dose.
• Probiotic altered gut microbiome, reducing constipation‑associated bacteria.
• No changes observed in goblet‑cell count or related gene expression.
• Authors recommend larger, longer human trials to confirm efficacy.

Pulse Analysis

Constipation affects roughly 15 % of adults worldwide, driving demand for treatments that avoid the side‑effects of conventional laxatives. Over the past decade, probiotics have moved from niche supplements to mainstream therapeutic candidates, as research links gut‑microbiome balance to bowel motility, short‑chain fatty‑acid production, and even serotonin synthesis. Companies ranging from biotech startups to agribusiness giants are investing in strain‑specific formulations, hoping to capture a share of the multi‑billion‑dollar digestive‑health market.

In a recent Nutrients paper, ADM’s BPL1 probiotic demonstrated dose‑dependent laxative activity in a rat model of loperamide‑induced constipation. Rats receiving the high‑dose regimen showed a marked rise in stool count, weight and moisture, alongside a reshaped microbial profile that reduced taxa previously associated with slowed transit. Notably, the intervention did not alter goblet‑cell density or the expression of genes governing intestinal fluid transport, hinting that BPL1 may enhance luminal water through mechanisms such as CFTR activation rather than structural mucosal changes.

For ADM, the study provides a proof‑of‑concept that could diversify its portfolio beyond traditional agricultural inputs into the fast‑growing functional‑food and probiotic space. However, translating animal data to human efficacy will require rigorously designed clinical trials, regulatory clearance, and clear differentiation from existing over‑the‑counter probiotic brands. Success could position ADM as a leader in microbiome‑driven therapeutics, while also delivering a safer, microbiota‑friendly option for the millions seeking relief from chronic constipation.